about
Electroacupuncture at points Baliao and Huiyang (BL35) for post-stroke detrusor overactivity.Association of urinary urgency and delay time of micturition in women with overactive bladder.A comparative study on the efficacy of solifenacin succinate in patients with urinary frequency with or without urgency.Predictors of urgency improvement after Holmium laser enucleation of the prostate in men with benign prostatic hyperplasia.Evaluation of female overactive bladder using urodynamics: relationship with female voiding dysfunction.Efficacy and safety of flexible dose fesoterodine in men and women with overactive bladder symptoms including nocturnal urinary urgency.Nocturia Think Tank: focus on nocturnal polyuria: ICI-RS 2011.Self-report measurement of lower urinary tract symptoms: a commentary on the literature since 2011.Validation of overactive bladder questionnaire (1-week recall version) in medically complex elderly patients with overactive bladder.A pooled analysis of the efficacy of fesoterodine for the treatment of overactive bladder, and the relationship between safety, co-morbidity and polypharmacy in patients aged 65 years or older.Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.Potential Biomarkers for Diagnosis of Overactive Bladder Patients: Urinary Nerve Growth Factor, Prostaglandin E2, and Adenosine Triphosphate.Effects of drug cessation after flexible-dose fesoterodine in patients with overactive bladder.Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.Safety and efficacy of flexible-dose fesoterodine in British subjects with overactive bladder: insights into factors associated with dose escalation.Long-term safety, tolerability and efficacy of flexible-dose fesoterodine in elderly patients with overactive bladder: open-label extension of the SOFIA trial.Efficacy and safety of fesoterodine treatment for overactive bladder symptoms in elderly women with and without hypertension.Comparison of the efficacy and safety of tolterodine 2 mg and 4 mg combined with an α-blocker in men with lower urinary tract symptoms (LUTS) and overactive bladder: a randomized controlled trial.Rate and associated factors of solifenacin add-on after tamsulosin monotherapy in men with voiding and storage lower urinary tract symptoms.Development and psychometric evaluation of the urgency questionnaire for evaluating severity and health-related quality of life impact of urinary urgency in overactive bladder.Defining urinary urgency: patient descriptions of "gotta go".Persistence of solifenacin therapy in patients with overactive bladder in the clinical setting: a prospective, multicenter, observational study.Safety and efficacy of fesoterodine fumarate in patients with overactive bladder: results of a post-marketing surveillance study in Korea.Long-term durability, functional outcomes, and factors associated with surgical failure of tension-free vaginal tape procedure.
P2860
Q34094538-A76DF3C5-4C93-4C6E-83CF-593AB8A0C513Q34267519-EC6A958D-A977-4606-B0F8-A4248B474FBFQ34524320-CC795F54-883B-4016-8938-A2FA6ED0295BQ36193649-CACDFBD9-839D-4A3A-9C0E-F02F6D9FF9C1Q36589375-A652AB5B-26B8-4553-BBA5-7588FB094012Q36919948-EBCBDC4D-DF46-49A8-A15B-D9655080F707Q37993502-16AD2B9C-F3E5-454E-99ED-D6EB5D0EFBC1Q38051160-3BD11C09-4593-4E6C-AC2A-487AC1FEEF88Q38854192-E96DAD6D-CDCA-4C3B-B451-B460A3DA1337Q39037375-6928A94B-3CBB-4890-908A-4FD9E186C1C6Q39211584-A4DD761D-0AA9-497F-B503-4246872750BDQ41997597-FC5BFA36-0956-4337-ACDF-EC484ABAE336Q42690377-840230F3-F6C3-47B4-931C-12DA44580931Q43859056-0F3F642A-312B-4D9E-8F2E-3D23689F356CQ44604387-8FEE0F69-2DA4-4442-AB06-40DD47CEBA2AQ46119071-9162F769-4F5E-492E-B836-5CD67F5AB536Q47336339-42A90E4F-5AA0-4341-BA5D-0131098220DCQ47980799-17033EAF-A49B-45EE-9BF0-A81CDA6E56B8Q48060968-6D369963-5AD3-4DCF-A90C-9438E2F9752CQ48072902-BA110CD8-1181-49BE-BEFA-5DA814BBDA2EQ48492533-EBD65662-73AF-4AA2-BDFB-A02A9D41F6E7Q50914391-E3363288-5A4F-47DA-B731-BFBD3A926BB6Q51392015-AEC3A006-74FD-4BFD-8EB0-CA298138C11BQ53523293-ACD774D0-3CF4-4AE8-AE7A-0687481BA39D
P2860
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Validation of the urinary sensation scale (USS).
@en
Validation of the urinary sensation scale
@nl
type
label
Validation of the urinary sensation scale (USS).
@en
Validation of the urinary sensation scale
@nl
prefLabel
Validation of the urinary sensation scale (USS).
@en
Validation of the urinary sensation scale
@nl
P2093
P2860
P356
P1476
Validation of the urinary sensation scale (USS).
@en
P2093
Karin S Coyne
Mary Kay Margolis
Vasudha Vats
P2860
P304
P356
10.1002/NAU.21005
P577
2011-01-20T00:00:00Z